Literature DB >> 20838959

Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate.

Naoto Takahashi, Yoshihiro Kameoka, Hiroyuki Tagawa, Hirobumi Saitoh, Tomoko Yoshioka, Naohito Fujishima, Atsushi Kitabayashi, Kaoru Takahashi, Makoto Hirokawa, Kenichi Sawada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20838959     DOI： 10.1007/s12185-010-0679-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.

Authors:  Naoto Takahashi; Ikuo Miura; Yoshimi Kobayashi; Masaaki Kume; Tomoko Yoshioka; Wataru Otane; Kaori Ohtsubo; Kaoru Takahashi; Atsushi Kitabayashi; Yoshinari Kawabata; Makoto Hirokawa; Hirokazu Nishijima; Ryo Ichinohasama; John Decoteau; Akira B Miura; Ken-Ichi Sawada
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 2.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael Deininger; Alois Gratwohl; François Guilhot; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Dietger Niederwieser; Richard Silver; Rudiger Hehlmann
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

3.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Authors:  A Hochhaus; S G O'Brien; F Guilhot; B J Druker; S Branford; L Foroni; J M Goldman; M C Müller; J P Radich; M Rudoltz; M Mone; I Gathmann; T P Hughes; R A Larson
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 11.528

4.  Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.

Authors:  N Takahashi; I Miura; K Saitoh; A B Miura
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

5.  [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].

Authors:  Fumiharu Yagasaki; Toshihiro Niwa; Aki Abe; Maho Ishikawa; Chiaki Kato; Kenji Ogura; Hiroshi Sasaki; Taiichi Kyo; Ituroh Jinnai; Masami Bessyo; Kouichi Miyamura
Journal:  Rinsho Ketsueki       Date:  2009-06

6.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

Authors:  Hugues de Lavallade; Jane F Apperley; Jamshid S Khorashad; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Journal:  J Clin Oncol       Date:  2008-06-02       Impact factor: 44.544

7.  Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

Authors:  Hagop Kantarjian; Susan O'Brien; Jianqin Shan; Xuelin Huang; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi-Kashani; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

Review 8.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.